Intravenous (IV) Ibuprofen

Intravenous (IV) Ibuprofen Comprehensive Study by Application (Pediatrics, Adults), Indication (Pain/Inflammatory, Fever), Form (Tablet, Capsule, Suspension, Other) Players and Region - Global Market Outlook to 2030

Intravenous (IV) Ibuprofen Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Intravenous (IV) Ibuprofen
Intravenous (IV) ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to reduce or treat pain, fever, and inflammation occurred due to a disease, operative procedures or trauma, and acute illness. The intravenous (IV) route for ibuprofen administration has a faster onset of action as compared to the other routes. IV ibuprofen is preferred for the management of post-operative and acute pain. The demand for ibuprofen has increased due to the side effects of opioid analgesics such as respiratory depression, allergic reactions, sedation, and gastrointestinal events.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Intravenous (IV) Ibuprofen market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Cumberland Pharmaceuticals (United States), Alveda Pharmaceuticals (Canada), CSL Limited (Australia), Sandor Medicaids (India), PT. Soho Industri Pharmasi (United States), Germin MED (Qatar), Grifols (Spain), Harbin Gloria Pharmaceuticals (China), Al Nabeel International (Oman) and Laboratorios Valmorca (Venezuela) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Intravenous (IV) Ibuprofen market by , Application (Pediatrics and Adults) and Region.



On the basis of geography, the market of Intravenous (IV) Ibuprofen has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by , the sub-segment i.e. will boost the Intravenous (IV) Ibuprofen market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Shifting trend towards the use of non-opioids drugs

Market Growth Drivers:
Increasing incidence of cancer, cardiovascular ailments, pain, headache, toothache, back pain, arthritis, and trauma

Challenges:
Lengthy approval process

Restraints:
Side effects associated with IV ibuprofen

Opportunities:
Rising demand among the consumers

Market Leaders and their expansionary development strategies
In January 2020, Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company with a focus on hospital acute care, has launched of Caldolor (ibuprofen) Injection in a ready-to-use bag that may be administered without dilution for pain relief.
In February 2024, Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, has launched of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US. this important new treatment option available for patients, helping to put better health within reach, every day


Key Target Audience
Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organisations, Hospital and Laboratories, Government Agencies and Organisations

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Pediatrics
  • Adults
By Indication
  • Pain/Inflammatory
  • Fever

By Form
  • Tablet
  • Capsule
  • Suspension
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing incidence of cancer, cardiovascular ailments, pain, headache, toothache, back pain, arthritis, and trauma
    • 3.3. Market Challenges
      • 3.3.1. Lengthy approval process
    • 3.4. Market Trends
      • 3.4.1. Shifting trend towards the use of non-opioids drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Intravenous (IV) Ibuprofen, by Application, Indication, Form and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Intravenous (IV) Ibuprofen (Value)
      • 5.2.1. Global Intravenous (IV) Ibuprofen by: Application (Value)
        • 5.2.1.1. Pediatrics
        • 5.2.1.2. Adults
      • 5.2.2. Global Intravenous (IV) Ibuprofen by: Indication (Value)
        • 5.2.2.1. Pain/Inflammatory
        • 5.2.2.2. Fever
      • 5.2.3. Global Intravenous (IV) Ibuprofen by: Form (Value)
        • 5.2.3.1. Tablet
        • 5.2.3.2. Capsule
        • 5.2.3.3. Suspension
        • 5.2.3.4. Other
      • 5.2.4. Global Intravenous (IV) Ibuprofen Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Intravenous (IV) Ibuprofen: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Cumberland Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alveda Pharmaceuticals (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CSL Limited (Australia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sandor Medicaids (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. PT. Soho Industri Pharmasi (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Germin MED (Qatar)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Grifols (Spain)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Harbin Gloria Pharmaceuticals (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Al Nabeel International (Oman)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Laboratorios Valmorca (Venezuela)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Intravenous (IV) Ibuprofen Sale, by Application, Indication, Form and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Intravenous (IV) Ibuprofen (Value)
      • 7.2.1. Global Intravenous (IV) Ibuprofen by: Application (Value)
        • 7.2.1.1. Pediatrics
        • 7.2.1.2. Adults
      • 7.2.2. Global Intravenous (IV) Ibuprofen by: Indication (Value)
        • 7.2.2.1. Pain/Inflammatory
        • 7.2.2.2. Fever
      • 7.2.3. Global Intravenous (IV) Ibuprofen by: Form (Value)
        • 7.2.3.1. Tablet
        • 7.2.3.2. Capsule
        • 7.2.3.3. Suspension
        • 7.2.3.4. Other
      • 7.2.4. Global Intravenous (IV) Ibuprofen Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Intravenous (IV) Ibuprofen: by Application(USD Million)
  • Table 2. Intravenous (IV) Ibuprofen Pediatrics , by Region USD Million (2018-2023)
  • Table 3. Intravenous (IV) Ibuprofen Adults , by Region USD Million (2018-2023)
  • Table 4. Intravenous (IV) Ibuprofen: by Indication(USD Million)
  • Table 5. Intravenous (IV) Ibuprofen Pain/Inflammatory , by Region USD Million (2018-2023)
  • Table 6. Intravenous (IV) Ibuprofen Fever , by Region USD Million (2018-2023)
  • Table 7. Intravenous (IV) Ibuprofen: by Form(USD Million)
  • Table 8. Intravenous (IV) Ibuprofen Tablet , by Region USD Million (2018-2023)
  • Table 9. Intravenous (IV) Ibuprofen Capsule , by Region USD Million (2018-2023)
  • Table 10. Intravenous (IV) Ibuprofen Suspension , by Region USD Million (2018-2023)
  • Table 11. Intravenous (IV) Ibuprofen Other , by Region USD Million (2018-2023)
  • Table 12. South America Intravenous (IV) Ibuprofen, by Country USD Million (2018-2023)
  • Table 13. South America Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 14. South America Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 15. South America Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 16. Brazil Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 17. Brazil Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 18. Brazil Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 19. Argentina Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 20. Argentina Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 21. Argentina Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 22. Rest of South America Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 23. Rest of South America Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 24. Rest of South America Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 25. Asia Pacific Intravenous (IV) Ibuprofen, by Country USD Million (2018-2023)
  • Table 26. Asia Pacific Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 27. Asia Pacific Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 28. Asia Pacific Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 29. China Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 30. China Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 31. China Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 32. Japan Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 33. Japan Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 34. Japan Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 35. India Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 36. India Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 37. India Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 38. South Korea Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 39. South Korea Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 40. South Korea Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 41. Taiwan Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 42. Taiwan Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 43. Taiwan Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 44. Australia Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 45. Australia Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 46. Australia Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 50. Europe Intravenous (IV) Ibuprofen, by Country USD Million (2018-2023)
  • Table 51. Europe Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 52. Europe Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 53. Europe Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 54. Germany Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 55. Germany Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 56. Germany Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 57. France Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 58. France Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 59. France Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 60. Italy Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 61. Italy Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 62. Italy Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 63. United Kingdom Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 64. United Kingdom Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 65. United Kingdom Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 66. Netherlands Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 67. Netherlands Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 68. Netherlands Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 69. Rest of Europe Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 70. Rest of Europe Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 71. Rest of Europe Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 72. MEA Intravenous (IV) Ibuprofen, by Country USD Million (2018-2023)
  • Table 73. MEA Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 74. MEA Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 75. MEA Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 76. Middle East Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 77. Middle East Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 78. Middle East Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 79. Africa Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 80. Africa Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 81. Africa Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 82. North America Intravenous (IV) Ibuprofen, by Country USD Million (2018-2023)
  • Table 83. North America Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 84. North America Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 85. North America Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 86. United States Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 87. United States Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 88. United States Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 89. Canada Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 90. Canada Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 91. Canada Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 92. Mexico Intravenous (IV) Ibuprofen, by Application USD Million (2018-2023)
  • Table 93. Mexico Intravenous (IV) Ibuprofen, by Indication USD Million (2018-2023)
  • Table 94. Mexico Intravenous (IV) Ibuprofen, by Form USD Million (2018-2023)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Intravenous (IV) Ibuprofen: by Application(USD Million)
  • Table 106. Intravenous (IV) Ibuprofen Pediatrics , by Region USD Million (2025-2030)
  • Table 107. Intravenous (IV) Ibuprofen Adults , by Region USD Million (2025-2030)
  • Table 108. Intravenous (IV) Ibuprofen: by Indication(USD Million)
  • Table 109. Intravenous (IV) Ibuprofen Pain/Inflammatory , by Region USD Million (2025-2030)
  • Table 110. Intravenous (IV) Ibuprofen Fever , by Region USD Million (2025-2030)
  • Table 111. Intravenous (IV) Ibuprofen: by Form(USD Million)
  • Table 112. Intravenous (IV) Ibuprofen Tablet , by Region USD Million (2025-2030)
  • Table 113. Intravenous (IV) Ibuprofen Capsule , by Region USD Million (2025-2030)
  • Table 114. Intravenous (IV) Ibuprofen Suspension , by Region USD Million (2025-2030)
  • Table 115. Intravenous (IV) Ibuprofen Other , by Region USD Million (2025-2030)
  • Table 116. South America Intravenous (IV) Ibuprofen, by Country USD Million (2025-2030)
  • Table 117. South America Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 118. South America Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 119. South America Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 120. Brazil Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 121. Brazil Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 122. Brazil Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 123. Argentina Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 124. Argentina Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 125. Argentina Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 126. Rest of South America Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 127. Rest of South America Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 128. Rest of South America Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 129. Asia Pacific Intravenous (IV) Ibuprofen, by Country USD Million (2025-2030)
  • Table 130. Asia Pacific Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 131. Asia Pacific Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 132. Asia Pacific Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 133. China Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 134. China Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 135. China Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 136. Japan Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 137. Japan Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 138. Japan Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 139. India Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 140. India Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 141. India Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 142. South Korea Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 143. South Korea Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 144. South Korea Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 145. Taiwan Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 146. Taiwan Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 147. Taiwan Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 148. Australia Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 149. Australia Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 150. Australia Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 151. Rest of Asia-Pacific Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 152. Rest of Asia-Pacific Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 153. Rest of Asia-Pacific Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 154. Europe Intravenous (IV) Ibuprofen, by Country USD Million (2025-2030)
  • Table 155. Europe Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 156. Europe Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 157. Europe Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 158. Germany Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 159. Germany Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 160. Germany Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 161. France Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 162. France Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 163. France Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 164. Italy Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 165. Italy Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 166. Italy Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 167. United Kingdom Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 168. United Kingdom Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 169. United Kingdom Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 170. Netherlands Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 171. Netherlands Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 172. Netherlands Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 173. Rest of Europe Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 174. Rest of Europe Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 175. Rest of Europe Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 176. MEA Intravenous (IV) Ibuprofen, by Country USD Million (2025-2030)
  • Table 177. MEA Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 178. MEA Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 179. MEA Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 180. Middle East Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 181. Middle East Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 182. Middle East Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 183. Africa Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 184. Africa Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 185. Africa Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 186. North America Intravenous (IV) Ibuprofen, by Country USD Million (2025-2030)
  • Table 187. North America Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 188. North America Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 189. North America Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 190. United States Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 191. United States Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 192. United States Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 193. Canada Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 194. Canada Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 195. Canada Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 196. Mexico Intravenous (IV) Ibuprofen, by Application USD Million (2025-2030)
  • Table 197. Mexico Intravenous (IV) Ibuprofen, by Indication USD Million (2025-2030)
  • Table 198. Mexico Intravenous (IV) Ibuprofen, by Form USD Million (2025-2030)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Intravenous (IV) Ibuprofen: by Application USD Million (2018-2023)
  • Figure 5. Global Intravenous (IV) Ibuprofen: by Indication USD Million (2018-2023)
  • Figure 6. Global Intravenous (IV) Ibuprofen: by Form USD Million (2018-2023)
  • Figure 7. South America Intravenous (IV) Ibuprofen Share (%), by Country
  • Figure 8. Asia Pacific Intravenous (IV) Ibuprofen Share (%), by Country
  • Figure 9. Europe Intravenous (IV) Ibuprofen Share (%), by Country
  • Figure 10. MEA Intravenous (IV) Ibuprofen Share (%), by Country
  • Figure 11. North America Intravenous (IV) Ibuprofen Share (%), by Country
  • Figure 12. Global Intravenous (IV) Ibuprofen share by Players 2023 (%)
  • Figure 13. Global Intravenous (IV) Ibuprofen share by Players (Top 3) 2023(%)
  • Figure 14. Global Intravenous (IV) Ibuprofen share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Cumberland Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 17. Cumberland Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 18. Alveda Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 19. Alveda Pharmaceuticals (Canada) Revenue: by Geography 2023
  • Figure 20. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 21. CSL Limited (Australia) Revenue: by Geography 2023
  • Figure 22. Sandor Medicaids (India) Revenue, Net Income and Gross profit
  • Figure 23. Sandor Medicaids (India) Revenue: by Geography 2023
  • Figure 24. PT. Soho Industri Pharmasi (United States) Revenue, Net Income and Gross profit
  • Figure 25. PT. Soho Industri Pharmasi (United States) Revenue: by Geography 2023
  • Figure 26. Germin MED (Qatar) Revenue, Net Income and Gross profit
  • Figure 27. Germin MED (Qatar) Revenue: by Geography 2023
  • Figure 28. Grifols (Spain) Revenue, Net Income and Gross profit
  • Figure 29. Grifols (Spain) Revenue: by Geography 2023
  • Figure 30. Harbin Gloria Pharmaceuticals (China) Revenue, Net Income and Gross profit
  • Figure 31. Harbin Gloria Pharmaceuticals (China) Revenue: by Geography 2023
  • Figure 32. Al Nabeel International (Oman) Revenue, Net Income and Gross profit
  • Figure 33. Al Nabeel International (Oman) Revenue: by Geography 2023
  • Figure 34. Laboratorios Valmorca (Venezuela) Revenue, Net Income and Gross profit
  • Figure 35. Laboratorios Valmorca (Venezuela) Revenue: by Geography 2023
  • Figure 36. Global Intravenous (IV) Ibuprofen: by Application USD Million (2025-2030)
  • Figure 37. Global Intravenous (IV) Ibuprofen: by Indication USD Million (2025-2030)
  • Figure 38. Global Intravenous (IV) Ibuprofen: by Form USD Million (2025-2030)
  • Figure 39. South America Intravenous (IV) Ibuprofen Share (%), by Country
  • Figure 40. Asia Pacific Intravenous (IV) Ibuprofen Share (%), by Country
  • Figure 41. Europe Intravenous (IV) Ibuprofen Share (%), by Country
  • Figure 42. MEA Intravenous (IV) Ibuprofen Share (%), by Country
  • Figure 43. North America Intravenous (IV) Ibuprofen Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Cumberland Pharmaceuticals (United States)
  • Alveda Pharmaceuticals (Canada)
  • CSL Limited (Australia)
  • Sandor Medicaids (India)
  • PT. Soho Industri Pharmasi (United States)
  • Germin MED (Qatar)
  • Grifols (Spain)
  • Harbin Gloria Pharmaceuticals (China)
  • Al Nabeel International (Oman)
  • Laboratorios Valmorca (Venezuela)
Select User Access Type

Key Highlights of Report


Mar 2024 202 Pages 92 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Intravenous (IV) Ibuprofen Quantitative research analysis
Intravenous (IV) Ibuprofen Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Cumberland Pharmaceuticals (United States), Alveda Pharmaceuticals (Canada), CSL Limited (Australia), Sandor Medicaids (India), PT. Soho Industri Pharmasi (United States), Germin MED (Qatar), Grifols (Spain), Harbin Gloria Pharmaceuticals (China), Al Nabeel International (Oman) and Laboratorios Valmorca (Venezuela) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Shifting trend towards the use of non-opioids drugs" is seen as one of major influencing trends for Intravenous (IV) Ibuprofen Market during projected period 2023-2030.
The Intravenous (IV) Ibuprofen market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Intravenous (IV) Ibuprofen Report?

Have a Query? Click Here

Other Related Reports

Anticholinergic Drugs Comprehensive Study by Type (Synthetic Compounds, Natural, Semi-Synthetic Compounds), Application (Overactive Bladder, Parkinson’s Disease, Chronic Obstructive Pulmonary Disease...
$ 3650
Candesartan Comprehensive Study by Application (Hypertension, Cardiovascular Risks, Chronic Kidney Diseases), Doses (4 mg, 8 mg, 16 mg, 32 mg), Distribution Channel (Hospital Pharmacies, Retail Pharm...
$ 3450
Antifibrinolytic Drugs Comprehensive Study by Drug Type (Amicar, Aminocaproic acid, Aprotinin, Cyklokapron, Fibrinogen, human, Lysteda, RiaSTAP, Tranexamic acid injection, Tranexamic acid oral, Trasy...
$ 3750
Botulism Illness Comprehensive Study by Type (Antibiotics, Antitoxins, Other), Application (Hospitals, Clinics, Other), Distribution Channel (OTC, Prescribed) Players and Region - Global Market Outlo...
$ 3500
Drug Eluting Beads Comprehensive Study by Type (LC Beads, QuadraSpheres, Oncozene Beads), Application (Hospitals, Specialized Clinics, Ambulatory Surgical Centers, Research Centers), Drug (Doxorubici...
$ 3800
Breast Cancer Monoclonal Antibodies Comprehensive Study by Type (Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies), Application (Hospitals, Retail Pharm...
$ 3500